140 related articles for article (PubMed ID: 28361519)
1. Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients.
Kim SJ; Shin IS; Eun SJ; Whangbo TK; Kim JW; Cho YS; Kim JC
Int Neurourol J; 2017 Mar; 21(1):29-37. PubMed ID: 28361519
[TBL] [Abstract][Full Text] [Related]
2. A Prospective, Open-Label Comparison of Tamsulosin plus Serenoa repens and Bovine Colostrum versus Tamsulosin Alone in the Treatment of Benign Prostatic Hyperplasia.
Di Maida F; Mari A; Rubino R; Minervini A; Carini M; Siena G
Urol Int; 2020; 104(5-6):351-355. PubMed ID: 31805571
[TBL] [Abstract][Full Text] [Related]
3. Tamsulosin for benign prostatic hyperplasia.
Wilt TJ; Mac Donald R; Rutks I
Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
[TBL] [Abstract][Full Text] [Related]
4. Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?
Argirović A; Argirović D
Vojnosanit Pregl; 2013 Dec; 70(12):1091-6. PubMed ID: 24450252
[TBL] [Abstract][Full Text] [Related]
5. General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis.
Shim SR; Kim JH; Choi H; Lee WJ; Kim HJ; Bae MY; Hwang SD; Kim KH; Bae JH; Yoon SJ
Curr Med Res Opin; 2015 Feb; 31(2):353-65. PubMed ID: 25350225
[TBL] [Abstract][Full Text] [Related]
6. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
Kawabe K; Yoshida M; Homma Y;
BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Roehrborn CG; Manyak MJ; Palacios-Moreno JM; Wilson TH; Roos EPM; Santos JC; Karanastasis D; Plastino J; Giuliano F; Rosen RC
BJU Int; 2018 Apr; 121(4):647-658. PubMed ID: 29044968
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial.
Cai JL; Zhou Z; Yang Y; Yan YF; Jing S; Na YQ
Chin Med J (Engl); 2016 Dec; 129(24):2899-2906. PubMed ID: 27958220
[TBL] [Abstract][Full Text] [Related]
9. Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction.
Zhou Z; Zheng X; Wu J; Gao Z; Xu Z; Cui Y
Am J Mens Health; 2019; 13(5):1557988319882597. PubMed ID: 31625449
[TBL] [Abstract][Full Text] [Related]
10. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
11. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
12. [Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial].
Glemain P; Coulange C; Billebaud T; Gattegno B; Muszynski R; Loeb G;
Prog Urol; 2002 Jun; 12(3):395-403; discussion 404. PubMed ID: 12189745
[TBL] [Abstract][Full Text] [Related]
13. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.
Gorgel SN; Sefik E; Kose O; Olgunelma V; Sahin E
Int Braz J Urol; 2013; 39(5):657-62. PubMed ID: 24267123
[TBL] [Abstract][Full Text] [Related]
14. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Garimella PS; Fink HA; Macdonald R; Wilt TJ
Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
[TBL] [Abstract][Full Text] [Related]
15. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
[TBL] [Abstract][Full Text] [Related]
16. Tadalafil Administered Once Daily for Treatment of Lower Urinary Tract Symptoms in Korean men with Benign Prostatic Hyperplasia: Results from a Placebo-Controlled Pilot Study Using Tamsulosin as an Active Control.
Kim SC; Park JK; Kim SW; Lee SW; Ahn TY; Kim JJ; Paick JS; Park NC; Park K; Min KS; Kraus SR; Secrest RJ; Elion-Mboussa A; Viktrup L
Low Urin Tract Symptoms; 2011 Sep; 3(2):86-93. PubMed ID: 26676392
[TBL] [Abstract][Full Text] [Related]
17. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
Gao ZW; Xin SY; Zhang JG; Ren XQ; Shang YF; Zhang W; Li HB; Xiao F; Shao CS
Zhonghua Nan Ke Xue; 2014 Mar; 20(3):239-43. PubMed ID: 24738461
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
20. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe].
Chapple ChR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernandez Fernandez E
Urologiia; 2012; (5):38-42, 44-5. PubMed ID: 23342615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
